Wadowski, Patricia P <br/><br/>
Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes.  [electronic resource] 

 -  Cardiovascular drugs and therapy  02 2020 
 - 53-63 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Observational Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-7241 
<br/><br/><label>Standard No.: </label>10.1007/s10557-019-06932-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Coronary Syndrome--blood<br/>Aged<br/>Blood Platelets--drug effects<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>P-Selectin--metabolism<br/>Percutaneous Coronary Intervention--adverse effects<br/>Platelet Aggregation--drug effects<br/>Platelet Aggregation Inhibitors--therapeutic use<br/>Platelet Glycoprotein GPIIb-IIIa Complex--metabolism<br/>Prasugrel Hydrochloride--therapeutic use<br/>Purinergic P2Y Receptor Antagonists--therapeutic use<br/>Receptors, Proteinase-Activated--metabolism<br/>Signal Transduction<br/>Ticagrelor--therapeutic use<br/>Toll-Like Receptors--metabolism<br/>Treatment Outcome